Article Sidebar
Views PDF: 258
CONSTRUCT THE MODEL OF COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS STANDARD THERAPY FOR THE INITIAL TREATMENT OF VENOUS THROMBOEMBOLISM AND PREVENTION OF RECURRENCE IN VIETNAM
Main Article Content
Abstract
Apixaban is a direct oral anticoagulant (DOACs) with several advantages over older oral anticoagulants, approved by the US Food and Drug Administration (FDA) for the treatment and prevention of venous thromboembolism in 2014. However, the high cost of the drug is a huge barrier when prescribing the drug in clinical practice, especially in developing countries like Vietnam. Therefore, it is necessary to consider the feasibility of clinical drug selection based on health technology assessment analysis, including cost-effectiveness analysis. One of the first and most important steps in a cost-effectiveness analysis is model building, especially for chronic diseases such as venous thromboembolism. With the modeling method combined with literature review and consultation with clinical experts, the research has built a cost-effectiveness analysis model based on Microsoft Excel 2016 software with output parameters are incremental cost – effectiveness ratios and sensitivity analysis. The model allows for evaluating the cost-effectiveness of apixaban compared with standard regimens for the initial treatment of venous thromboembolism and prevention of recurrence in Vietnam.
Article Details
Keywords
cost - effectiveness, model, apixaban, venous thromboembolism
References
2. De Jong LA, Dvortsin E, Janssen KJ et al. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical Therapeutics 2017;39:288–302.
3. Elías I, Oyagüez I, Álvarez-Sala LA et al. Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism. Farm Hosp. 2016;40(3):187-208.
4. Glickman A, Brennecke A, Tayebnejad A et al. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. Gynecologic Oncology. 2020:1-6.
5. Gómez-Cerezo J.F, Gómez-Arrayás I, Suárez-Fernández C et al. Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement. Rev Esp Cir Ortop Traumatol. 2012;56(6):460-468.
6. Kimpton M, Kumar S, Wells PS et al. Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. Bloodjournal Blood blood. 2019;134:329.
7. Lanitis T, Leipold R, Hamilton M et al. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. Clinical Therapeutics. 2016;2(2):1-15.
8. Quon P, Le HH, Raymond V et al. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Journal of Medical Economics. 2016.
9. Revankar N, Patterson J, Kadambi A et al. A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for PostSurgical Venous Thromboembolism Prevention. Postgraduate Medicine 2013;125(4):141-152.
10. Saleh ASA, Berrigan P, Anderson D et al. Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation. Can J Hosp Pharm. 2017;70(3):188-198.
11. Yan X, Gu X, Xu Z et al. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. Adv Ther. 2017;34:466–480.
12. Yan X, Gu X, Zhou L et al. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. Clin Drug Investig. 2016.